… In this study of KRAS-mutant lung cancer models, combining MEK inhibition with
immunotherapies such as anti-PD-1 or anti-PD-L1 antibodies showed a synergistic effect and …

… resistance, combination therapy targeting BRAF and MEK, a … BRAF and MEK inhibitor
combinations have been approved … for various BRAF plus MEK combination regimens in three …

… Here, we provide preclinical rationale and clinical trial data for combined RAF and MEK
inhibition against tumors with activated non-V600 BRAF mutants. While the combination had a …

… with RAF and MEK inhibitors in patients with primary brain tumors and describe ongoing
clinical trials of RAF inhibitors in … this, RAF inhibitors have been combined with MEK inhibitors in …

… type II RAF inhibitors and a MEK inhibitor led to a stronger ERK pathway inhibition and growth
… with CRAF oncogene dependency to the combination of type II RAF and MEK inhibition. …

… We observed enhanced antitumor efficacy for RAF dimer and MEK inhibitor combination, …
reports suggesting RAF dimer or pan-RAF inhibitor in combination with MEK inhibitor may be a …

… A rationally designed combination of RAF and MEK inhibitors based on their conformation
selectivity achieved increased efficacy and a high therapeutic index when used to target …

… of a concomitant triple-therapy combination of BRAF and MEK inhibitors with anti-PD-1 in …
1 trial, a combination of approved doses of the BRAF inhibitor dabrafenib, the MEK inhibitor …

… MEK inhibitor (MEKi) monotherapy provides limited clinical benefits but may serve as a
foundation for combination therapies. Here, we showed that combining a type II RAF inhibitor (…

… to single‐agent tyrosine kinase inhibitors or to treat cancers with … combination binimetinib
(MEK inhibitor) and buparlisib (PI3K inhibitor) in patients harboring alterations in the RAS/RAF …